【摘 要】
：
Recent advances in the field of tissue engineering and regenerative medicine have offered new therapeutic opportunities for repairing damaged tissues and organs.
【机 构】
：
Wake Forest Institute for Regenerative Medicine,Wake Forest School of Medicine Winston-Salem,NC U.S.
【出 处】
：
2013 Annual Meeting of the Asia Pacific Chapter of the Tissu
论文部分内容阅读
Recent advances in the field of tissue engineering and regenerative medicine have offered new therapeutic opportunities for repairing damaged tissues and organs.
其他文献
Recently, application of tissue engineering products has been rapidly developed by new strategy.That is in vivo tissue engineering where the used cells are taken from patents body himself.
In tissue engineering and regenerative medicine, suitable scaffold is very essential for tissue repair by cell growth.The extra cell matrix (ECM) in special tissue should be the best scaffold as build
Introduction As a new class of bioactive materials for bone regeneration, ordered mesoporous bioactive glasses (MBG) have attracted much attention in recent years.
Bone defects occur in a wide variety of clinical situations, and their reconstruction to provide unique bone-like structures and functions is a necessary step in the patients rehabilitation.
Critical-size bone defects are among the more difficult regenerative therapies to successfully achieve.The implantation of engineered constructs obtained by seeding osteogenic cells, such as Mesenchym
During the past two decades, research on ceramic scaffolds for bone regeneration has progressed rapidly;however, currently available porous scaffolds remain unsuitable for load-bearing applications.
Phosphate based glasses are a unique group of materials in that they are degradable and also the rate of degradation may be altered over several orders of magnitude by simply altering the glass compos
Introduction Pelvic organ prolapse (POP) is the herniation of the pelvic organs into the vagina.Current support meshes lead to problems of wall erosion and poor integration, partly due to inferior mec
We have used both mesenchymal stem cells (MSC)andinduced pluripotent stem cells (iPSC)as sources of human cardiomyocytesto grow vascularised cardiac tissue in chambers in vivo.
Cell transplantation is a promising approach for patients with myocardial infarction.However, following injection, retention of the transplanted cells in the injected area remains a central issue, whi